Payment overview · 2025
General Payments
$316.31
15 reported records · 10 companies
Healthcare provider profile · identity verified
Norris W Hsu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOFFMAN ESTATES, IL · NPI 1508961350
Verified facts
What the public records show
CMS Open Payments records show Norris W Hsu, MD received $316.31 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.49 | 23.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38.62 | 12.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.48 | 11.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.97 | 11.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $35.56 | 11.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.12 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.27 | 6.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.99 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.60 | 4.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.21 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.31 | 14 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 442 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 301 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 76 |
| Losartan Potassium | Losartan Potassium | 183 | 58 |
| Lisinopril | Lisinopril | 168 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 58 |
| Omeprazole | Omeprazole | 141 | 51 |
| Simvastatin | Simvastatin | 131 | 46 |
| Metformin Hcl | Metformin Hcl | 114 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 36 |
| Alprazolam | Alprazolam | 100 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 31 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 21 |
| Gabapentin | Gabapentin | 64 | 21 |
| Montelukast Sodium | Montelukast Sodium | 60 | 21 |
| Meloxicam | Meloxicam | 56 | 31 |
| Ezetimibe | Ezetimibe | 53 | 19 |
| Lorazepam | Lorazepam | 53 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 24 |
| Allopurinol | Allopurinol | 51 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 20 |
| Furosemide | Furosemide | 48 | 28 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Famotidine | Famotidine | 45 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 23 |
| Methylprednisolone | Methylprednisolone | 44 | 37 |
| Finasteride | Finasteride | 43 | 13 |
| Jardiance | Empagliflozin | 43 | 16 |
| Glimepiride | Glimepiride | 42 | 14 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | 13 |
| Irbesartan | Irbesartan | 39 | suppressed |
| Eliquis | Apixaban | 38 | 12 |
| Valsartan | Valsartan | 38 | 12 |
| Atenolol | Atenolol | 37 | 13 |
| Bupropion Xl | Bupropion Hcl | 33 | 13 |
| Trazodone Hcl | Trazodone Hcl | 33 | 16 |
| Potassium Chloride | Potassium Chloride | 32 | 12 |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 13 |
| Telmisartan | Telmisartan | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Prednisone | Prednisone | 24 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.31 · 15 records | Lilly USA, LLC | AIRSUPRA, CAPVAXIVE, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, NEXLETOL, REPATHA, SPRAVATO, SYNTHROID, The Cologuard Plus Collection Kit, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error